17 Feb 2017 --- For the first time, scientists have proven that intermittent fasting can have health benefits in humans. Prior studies have indicated a range of health benefits in mice, but the new study from researchers at the USC Leonard Davis School of Gerontology, shows how human participants can lose weight and reduce their risk of life-threatening disease without any changes to their regular diet.

The study looked at 71 adults who were placed on three cycles of a low-calorie, "fasting-mimicking" diet.

The phase II trial, say the conducting researchers at the USC Leonard Davis School of Gerontology, demonstrated a host of benefits from the regimen.

The diet reduced cardiovascular risk factors including blood pressure, signs of inflammation (measured by C-reactive protein levels), as well as fasting glucose and reduced levels of IGF-1, a hormone that affects metabolism.

It also shrank waistlines and resulted in weight loss, both in total body fat and trunk fat, but not in muscle mass.

In effect, the diet reduced the study participants' risks for cancer, diabetes, heart disease and other age-related diseases.

“This study provides evidence that people can experience significant health benefits through a periodic, fasting-mimicking diet that is designed to act on the aging process,” said Valter Longo, director of the USC Longevity Institute and a professor of biological sciences for USC Davis and Dornsife.

“Prior studies have indicated a range of health benefits in mice, but this is the first randomized clinical trial with enough participants to demonstrate that the diet is feasible, effective and safe for humans.”

“Larger FDA studies are necessary to confirm its effects on disease prevention and treatment,” he added.

One hundred people participated in the trial from April 2013 to July 2015. The participants, ages 20 to 70 and all generally healthy, were divided into two groups for the randomized trial. Participants in the first group, the control group, were asked to continue their normal eating habits for three months.

People in the second group were placed on a three-month test of the fasting-mimicking diet.

Those on the special diet were required to eat food products supplied by the nutrition company L-Nutra during the fasting periods of five days each month.

The diet, which was designed to mimic the results of a water-only fast, allowed for participants to consume between 750 and 1,100 calories per day.

The meals for the fast-mimicking diet contained precise proportions of proteins, fats and carbohydrates.

After three months, participants in the control group were moved onto the special diet. The researchers found that participants on the fasting-mimicking diet lost an average of about 6 pounds. Their waistlines shrank by 1 to 2 inches, and their systolic blood pressure, which was in the normal range when the study began, dropped by 4.5 mmHG, while their diastolic blood pressure dropped by 3.1 mmHg.

Also, their levels of IGF-1 dropped to between 21.7 ng/mL and 46.2 ng/mL, reaching a range associated with lower cancer risk.

“After the first group completed their three months on the fasting diet, we moved over participants in the control group to see if they also would experience similar results,” Longo said.

“We saw similar outcomes, which provides further evidence that a fasting-mimicking diet has effects on many metabolic and disease markers.”

“Our mouse studies using a similar fasting-mimicking diet indicate that these beneficial effects are caused by multi-system regeneration and rejuvenation in the body at the cellular and organ levels.”

“Our participants retained those effects, even when they returned to their normal daily eating habits,” he added.

The researchers also noted that participants considered “at risk” because they had risk factors such as high IGF-1, cholesterol, blood pressure or blood sugar levels, made significant progress toward better health. For example, baseline fasting glucose levels for participants with high blood sugar levels (putting them at risk for diabetes) dropped into the healthy range, below 99 mg/dl -- but these levels didn't drop among participants who already had healthy levels at the beginning of the study.

Cholesterol was reduced by 20 mg/dl in those with high cholesterol levels, and by about 5 mg/dl in all participants.

“Fasting seems to be the most beneficial for patients who have the great risk factors for disease, such as those who have high blood pressure or pre-diabetes or who are obese,” Longo said.

The researchers had invited participants in the study for one last set of tests three months later, at the end of the diet. The research team found that the beneficial effects -- from weight loss, smaller waistlines and lower glucose, blood pressure and IGF-1 levels -- were sustained. The next step for researchers is a large, FDA phase III clinical trial to test the FMD on patients diagnosed with age-related diseases or at high risk for them.

The researchers said further investigation will determine whether the benefits of the diet can continue for several months.

Related Articles

13 Dec 2017 --- Biotechnology company Nuritas has innovative plans for using artificial intelligence (AI) to relieve the potential burden of future global health issues. These plans were outlined during its Future of Nutrition Summit held the day before FiE 2017 in Frankfurt, during which Nuritas Commercial Manager Neil Foster outlined the company’s use of AI for data mining for bioactive peptides, specific molecules with “tremendous” health benefits.

13 Dec 2017 --- One of the major issues to be discussed at Vitafoods Europe 2018 will be how personalized nutrition can break out of its niche and achieve mass market appeal, the organizers of the global nutraceutical event have announced. Advances in genomics and wearable technology have created new opportunities for products tailored to individual consumers. And in a new poll conducted by the organizers, personalized nutrition ranks as one of the most important industry trends for 2018, behind only clean label and scientifically supported health claims.

13 Dec 2017 --- Frutarom has acquired AB-Fortis activities, including a patent-protected micro-encapsulation technology that enables delivery of iron with increased biological absorption. Frutarom announced the signing of an agreement with AB-Biotics S.A. of Spain for the acquisition of the activity of AB-Fortis in November.

13 Dec 2017 --- Kappa Bioscience AS, maker of K2Vital vitamin K2 MK-7, has appointed Garnet Pigden and New Jersey-based D2C to head-up the continued development of Kappa’s position in the US market. The appointment spans the establishment of strategy, infrastructure, partnerships and key accounts in support of an overall objective of solidifying vitamin K2 in mainstream US markets and channels, according to Kappa.

12 Dec 2017 --- Exhibitors at FiE 2017 in Frankfurt showed a sustained focus on high protein concepts, with a number of notable innovations in the area of dairy-related ingredients. NutritionInsight looks at just a few of the offerings showcased at this year’s event.